Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
CTR20220256Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab, bevacizumab, sorafenib in hepatocellular carcinoma (HCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Nov 2020; status: completed.
02
Drugs
toripalimabbevacizumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20220256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220256.